Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 362,152 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 10,000 · Balance 372,152 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Row 2 · 2026-08-10 · Sale · Disposed 10,000 · Balance 362,152 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2033-04-05 | Direct | 110,546 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 10,000 · Balance 110,546 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Relay Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08 | Direct | 32,947 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001470831-26-000813 · wk-form4_1786565953.xml · derivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,546 Underlying: Common Stock · 10,000 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 10,000 | $27.98 | $279,750.00 |
DisclosureSEC source: 0001470831-26-000813 · wk-form4_1786565953.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,152 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:19 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 10,000 | $3.79 | $37,898.00 |
DisclosureSEC source: 0001470831-26-000813 · wk-form4_1786565953.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001470831-26-000714 · wk-form4_1784060551.xml · derivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,546 Underlying: Common Stock · 10,000 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 28 | $29.68 | $831.04 |
DisclosureSEC source: 0001470831-26-000714 · wk-form4_1784060551.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,152 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 9,972 | $28.42 | $283,367.34 |
DisclosureSEC source: 0001470831-26-000714 · wk-form4_1784060551.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,180 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.13 to $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:22 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 10,000 | $3.79 | $37,898.00 |
DisclosureSEC source: 0001470831-26-000714 · wk-form4_1784060551.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 32,947 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-265913 · ownership.xml · derivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,947 Underlying: Common Stock · 32,947 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:07 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-036885 · wk-form4_1779307664.xml · derivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,107 Underlying: Common Stock · 15,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:07 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 2,978 | $20.35 | $60,596.64 |
DisclosureSEC source: 0001628280-26-036885 · wk-form4_1779307664.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,152 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:07 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 12,022 | $19.96 | $239,981.96 |
DisclosureSEC source: 0001628280-26-036885 · wk-form4_1779307664.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 365,130 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.52 to $20.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:07 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 15,000 | $3.79 | $56,847.00 |
DisclosureSEC source: 0001628280-26-036885 · wk-form4_1779307664.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| April 20, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · derivative · entry 9 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,107 Underlying: Common Stock · 15,000 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F6 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 15,000 | $23.61 | $354,145.50 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · nonDerivative · entry 5 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,152 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.355 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 20, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 15,000 | $3.79 | $56,847.00 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · nonDerivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,080 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · derivative · entry 8 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 558,432 Underlying: Common Stock · 7,080 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,454 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · derivative · entry 7 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,546 Underlying: Common Stock · 7,454 shares Expires 2033-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,226 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · derivative · entry 6 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,684 Underlying: Common Stock · 8,226 shares Expires 2032-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following October 4, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 7,080 | $5.45 | $38,612.20 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 362,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 7,454 | $3.79 | $28,249.17 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 23:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 8,226 | $4.44 | $36,497.94 |
DisclosureSEC source: 0001628280-26-026089 · wk-form4_1776727626.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 347,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,596 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · derivative · entry 9 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,107 Underlying: Common Stock · 1,596 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 1,596 | $18.95 | $30,246.27 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 6 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 1,596 | $3.79 | $6,048.52 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 5 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,905 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · derivative · entry 8 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,703 Underlying: Common Stock · 6,905 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 6,905 | $18.78 | $129,704.90 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 6,905 | $3.79 | $26,168.57 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,499 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · derivative · entry 7 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,608 Underlying: Common Stock · 6,499 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 6,499 | $18.84 | $122,414.51 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 21:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 6,499 | $3.79 | $24,629.91 |
DisclosureSEC source: 0001628280-26-020236 · wk-form4_1774040575.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:47 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,766 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-016874 · wk-form4_1773262035.xml · derivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,107 Underlying: Common Stock · 36,766 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:47 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 36,766 | $19.17 | $704,657.16 |
DisclosureSEC source: 0001628280-26-016874 · wk-form4_1773262035.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:47 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 36,766 | $3.79 | $139,335.79 |
DisclosureSEC source: 0001628280-26-016874 · wk-form4_1773262035.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 06, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,817 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · derivative · entry 9 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,873 Underlying: Common Stock · 3,817 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 3,817 | $18.75 | $71,571.80 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 6 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 06, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 3,817 | $3.79 | $14,465.67 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 5 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 343,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 05, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,786 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · derivative · entry 8 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,690 Underlying: Common Stock · 1,786 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 1,786 | $18.74 | $33,464.10 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 4 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.795, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 05, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 1,786 | $3.79 | $6,768.58 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 341,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,631 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · derivative · entry 7 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,476 Underlying: Common Stock · 2,631 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F5 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 2,631 | $18.73 | $49,288.63 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,392 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:27 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 2,631 | $3.79 | $9,970.96 |
DisclosureSEC source: 0001628280-26-015778 · wk-form4_1772843254.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:37 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $16.76 | $0.00 |
DisclosureSEC source: 0001628280-26-005484 · wk-form4_1770241022.xml · derivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,500 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0002034671-25-000012 · wk-form4_1766098974.xml · derivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,512 Underlying: Common Stock · 29,500 shares Expires 2033-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:02 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 29,500 | $5.45 | $160,884.15 |
DisclosureSEC source: 0002034671-25-000012 · wk-form4_1766098974.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:40 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,163 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034671-25-000009 · wk-form4_1764114037.xml · derivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,107 Underlying: Common Stock · 41,163 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:40 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 41,163 | $18.86 | $776,428.85 |
DisclosureSEC source: 0002034671-25-000009 · wk-form4_1764114037.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,892 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:40 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionCommon Stock | 41,163 | $3.79 | $155,999.54 |
DisclosureSEC source: 0002034671-25-000009 · wk-form4_1764114037.xml · nonDerivative · entry 1 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:11 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,103 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0002034671-25-000006 · wk-form4_1760991057.xml · derivative · entry 3 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,270 Underlying: Common Stock · 24,103 shares Expires 2033-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:11 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | SaleCommon Stock | 24,103 | $18.83 | $453,760.67 |
DisclosureSEC source: 0002034671-25-000006 · wk-form4_1760991057.xml · nonDerivative · entry 2 Mazumdar Claire · CIK 0002034671 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,892 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.